Disease Area

selinexor

Rights

XPOVIO (selinexor) is approved in the U.S. in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody

PreclinicalPhase IPhase IIPhase III
Approved